Overview
Sponsor-declared trial summary
Prevention of ischemic stroke in patients post acute non-cardioembolic ischemic stroke or high-risk transient ischemic attack
Efficacy To evaluate whether the oral FXIa inhibitor asundexian is superior to placebo on top of background antiplatelet therapy in reducing ischemic stroke in patients after an acute non-cardioembolic ischemic stroke or high-risk Transient ischemic attack (TIA) Safety To compare the incidence of International Society …
Key facts
- Sponsor
- Bayer AG
- Participant type
- Patients
- Age range
- 18-64 years, 65+ years
- Gender
- Male and Female
- Therapeutic area
- Diseases [C] - Cardiovascular Diseases [C14]
- Trial duration
- 18 Jan 2023 → 24 Oct 2025
- Decision date (initial)
- 2023-10-02
- Transition trial
- Yes
- Low-intervention
- No
- Rare-disease indication
- No
- Vulnerable population
- Yes
- Funding sources
- Bayer AG, D-51368, Leverkusen, Germany
External identifiers
- EU CT number
- 2023-503793-20-00
- EudraCT number
- 2022-001067-27
- ClinicalTrials.gov
- NCT05686070
Trial design
CTIS Part I — objectives, methods, condition coding
Main objective
Scope: Others, Safety, Pharmacokinetic, Pharmacogenetic, Pharmacodynamic, Efficacy, Prophylaxis
Efficacy
To evaluate whether the oral FXIa inhibitor asundexian is superior to placebo on top of background antiplatelet therapy in reducing ischemic stroke in patients after an acute non-cardioembolic ischemic stroke or high-risk Transient ischemic attack (TIA)
Safety
To compare the incidence of International Society on Thrombosis and Hemostasis (ISTH) major bleeding for asundexian and placebo on top of antiplatelet therapy in patients after an acute noncardioembolic ischemic stroke or high-risk TIA
Secondary objectives 3
- Efficacy To evaluate whether asundexian is superior to placebo on top of antiplatelet therapy in reducing the occurrence of composite and individual efficacy endpoints
- Safety To compare asundexian and placebo on top of antiplatelet therapy with respect to individual bleeding endpoints
- Net clinical benefit To further compare the benefit and risk of asundexian and placebo with respect to a composite of efficacy and safety endpoints
Conditions and MedDRA coding
Prevention of ischemic stroke in patients post acute non-cardioembolic ischemic stroke or high-risk transient ischemic attack
| Version | Level | Code | Term | System organ class |
|---|---|---|---|---|
| 20.1 | LLT | 10072760 | Transient ischemic attack | 10029205 |
| 20.0 | PT | 10049165 | Cerebrovascular accident prophylaxis | 100000004865 |
| 22.1 | LLT | 10055221 | Ischemic stroke | 10029205 |
Regulatory references
- Scientific advice from competent authorities
- European Medicines Agency, Pharmaceuticals And Medical Devices Agency
- EMA paediatric investigation plan (PIP)
- EMEA-003144-PIP01-21
- Plan to share IPD
- No
- IPD plan description
- Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
| EU CT number | Title | Sponsor |
|---|---|---|
| 2023-503794-38-00 | (19767 OCEANIC-AF) A multicenter, international, randomized, active comparator-controlled, double-blind, double-dummy, parallel-group, 2-arm, Phase 3 study to compare the efficacy and safety of the oral FXIa inhibitor asundexian (BAY 2433334) with apixaban for the prevention of stroke or systemic embolism in male and female participants aged 18 years and older with atrial fibrillation at risk for stroke | Bayer AG |
Eligibility criteria
Principal inclusion / exclusion criteria as submitted by sponsor
Inclusion criteria 3
- Participants must be >= 18 years of age
- Acute non-cardioembolic stroke or high-risk TIA
- Systemic or cerebrovascular atherosclerosis or acute non-lacunar infarct
Exclusion criteria 3
- Ischemic stroke <= 7 days before the index event
- Index stroke following procedures or strokes due to other rare causes
- History of atrial fibrillation/flutter, left ventricular thrombus, mechanic valve or other cardioembolic source of stroke requiring anticoagulation
Endpoints
Primary and secondary outcome measures (English text)
Primary endpoints 2
- Time to first occurrence of ischemic stroke
- Time to first occurrence of ISTH major bleeding
Secondary endpoints 16
- Time to first occurrence of all strokes (ischemic and hemorrhagic)
- Time to first occurrence of composite of Cardiovascular (CV) death, myocardial infarction (MI) or stroke
- Time to first occurrence of composite of all-cause mortality, MI or stroke
- Time to first occurrence of disabling stroke (mRS >= 3 at 90 days)
- Time to first occurrence of all-cause mortality
- Time to first occurrence of transient ischemic attack (TIA)
- Time to first occurrence of composite of ISTH major or clinically relevant non-major bleeding
- Time to first occurrence of ISTH clinically relevant non-major bleeding
- Time to first occurrence of symptomatic intracranial hemorrhage
- Time to first occurrence of hemorrhagic stroke
- Time to first occurrence of fatal bleeding
- Time to first occurrence of minor bleeding
- Time to first occurrence of composite of ischemic stroke or ISTH major bleeding
- Time to first occurrence of composite of CV death, all stroke, MI or ISTH major bleeding
- Time to first occurrence of composite of all-cause mortality, disabling stroke, fatal bleeding, symptomatic intracranial hemorrhage
- Time to first occurrence of ischemic stroke in the first 90 days
Investigational products
Investigational medicinal products (IMPs), comparators, placebo, auxiliary
Test 1
PRD7514744 · Product
- Active substance
- Asundexian
- Pharmaceutical form
- FILM-COATED TABLET
- Route of administration
- ORAL USE
- Max daily dose
- 50 mg milligram(s)
- Max total dose
- 47500 mg milligram(s)
- Max treatment duration
- 31 Month(s)
- Authorisation status
- Not Authorised
- MA holder
- BAYER AG
- Paediatric formulation
- No
- Orphan designation
- No
Placebo 1
Placebo for test product BAY 2433334
N/A · Product
- Other product name
- N/A
- Pharmaceutical form
- N/A
- ATC code
- N/A — N/A
- Marketing authorisation
- N/A
- MA holder
- N/A
- MA country
- Iceland
- Paediatric formulation
- No
Sponsors and contacts
Sponsor organisations, regulatory contacts, third parties
Bayer AG
- Sponsor organisation
- Bayer AG
- Address
- Kaiser-Wilhelm-Allee 1, Wiesdorf Wiesdorf
- City
- Leverkusen
- Postcode
- 51373
- Country
- Germany
Scientific contact point
- Organisation
- Bayer AG
- Contact name
- Therapeutic Area Head
Public contact point
- Organisation
- Bayer AG
- Contact name
- Therapeutic Area Head
Third parties 6
| Organisation | City, country | Duties |
|---|---|---|
| Nuvisan GmbH ORG-100011873
|
Neu-Ulm, Germany | Other |
| Labcorp Central Laboratory Services LP ORG-100032236
|
Indianapolis, United States | Other, Laboratory analysis |
| Mlm Medical Labs GmbH ORG-100043721
|
Mönchengladbach, Germany | Other |
| Suvoda LLC ORG-100043523
|
Conshohocken, United States | Interactive response technologies (IRT) |
| PHRI Population Health Research Institute International ORG-100030045
|
Hamilton, Canada | Other |
| University Of Calgary ORG-100023448
|
Calgary, Canada | Other |
Locations
20 EU/EEA countries · 275 investigational sites
By country
| Country | MS status | Planned subjects | Sites |
|---|---|---|---|
| Austria | Ended | 150 | 11 |
| Belgium | Ended | 220 | 11 |
| Bulgaria | Ended | 440 | 16 |
| Czechia | Ended | 245 | 15 |
| Denmark | Ended | 200 | 8 |
| Finland | Ended | 110 | 5 |
| France | Ended | 576 | 29 |
| Germany | Ended | 290 | 25 |
| Greece | Ended | 455 | 17 |
| Hungary | Ended | 250 | 16 |
| Italy | Ended | 425 | 22 |
| Latvia | Ended | 118 | 4 |
| Lithuania | Ended | 100 | 5 |
| Netherlands | Ended | 125 | 10 |
| Norway | Ended | 60 | 6 |
| Poland | Ended | 240 | 14 |
| Portugal | Ended | 325 | 12 |
| Slovakia | Ended | 250 | 15 |
| Spain | Ended | 550 | 26 |
| Sweden | Ended | 94 | 8 |
| Rest of world
Canada, Taiwan, United Kingdom, China, Korea, Republic of, Switzerland, Turkey, United States, Brazil, Colombia, Russian Federation, Israel, Singapore, India, Australia, Japan, Argentina, Malaysia
|
— | 6,785 | — |
Investigational sites
Country notifications
Trial-start, recruitment-start, end and early-termination notifications submitted per Member State
| Country | Trial start | Trial end | Recruitment start | Recruitment end | Early termination |
|---|---|---|---|---|---|
| Austria | 2023-01-18 | 2025-10-23 | 2023-01-31 | 2025-02-19 | |
| Belgium | 2023-02-21 | 2025-10-23 | 2023-03-01 | 2025-02-19 | |
| Bulgaria | 2023-03-02 | 2025-10-23 | 2023-03-06 | 2025-02-19 | |
| Czechia | 2023-02-16 | 2025-10-23 | 2023-03-15 | 2025-02-19 | |
| Denmark | 2023-01-30 | 2025-10-23 | 2023-01-31 | 2025-02-19 | |
| Finland | 2023-02-02 | 2025-10-23 | 2023-02-07 | 2025-02-19 | |
| France | 2023-02-22 | 2025-10-23 | 2023-02-28 | 2025-02-19 | |
| Germany | 2023-04-03 | 2025-10-23 | 2023-04-04 | 2025-02-19 | |
| Greece | 2023-02-21 | 2025-10-23 | 2023-02-22 | 2025-02-19 | |
| Hungary | 2023-01-20 | 2025-10-23 | 2023-01-26 | 2025-02-19 | |
| Italy | 2023-02-09 | 2025-10-23 | 2023-02-14 | 2025-02-19 | |
| Latvia | 2023-02-14 | 2025-10-23 | 2023-02-19 | 2025-02-19 | |
| Lithuania | 2023-03-10 | 2025-10-23 | 2023-03-24 | 2025-02-19 | |
| Netherlands | 2023-02-27 | 2025-10-23 | 2023-03-01 | 2025-02-19 | |
| Norway | 2023-03-03 | 2025-10-23 | 2023-05-04 | 2025-02-19 | |
| Poland | 2023-02-27 | 2025-10-23 | 2023-03-01 | 2025-02-19 | |
| Portugal | 2023-05-08 | 2025-10-23 | 2023-05-12 | 2025-02-19 | |
| Slovakia | 2023-02-01 | 2025-10-23 | 2023-02-09 | 2025-02-19 | |
| Spain | 2023-01-27 | 2025-10-23 | 2023-02-10 | 2025-02-19 | |
| Sweden | 2023-07-05 | 2025-10-23 | 2023-08-07 | 2025-02-19 |
Results and documents
Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial
Documents 124 files
Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.
| Type | Title | Version |
|---|---|---|
| Protocol (for publication) | D1_Protocol 2023-503793-20-00_EL_for publication | 3 |
| Protocol (for publication) | D1_Protocol 2023-503793-20-00_EN_For Publication | 3 |
| Recruitment arrangements (for publication) | EC-IRB submission ES 20604 recruitment information For Publication | 1 |
| Recruitment arrangements (for publication) | EC-IRB submission PT 20604 Recruitment information For publication | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements_CZ_CZ_Procedure Template_public | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements_EN_AT_Procedure Template_public | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements_EN_ES_Procedure Template_public | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements_EN_IT_procedure template_public | 2 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements_EN_NL_Procedure Template_public | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements_EN_NO_Recruitment and Informed Consent Procedure_public | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements_EN_Procedure Template_public | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements_EN_PT_Procedure Template_public | 1 |
| Recruitment arrangements (for publication) | K1_Recruitment arrangements_FR_FR_Procedure Template_public | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment materials_FR_FR_ICF Tabletop_public | 1.1 |
| Recruitment arrangements (for publication) | K2_Recruitment materials_FR_FR_Patient Booklet_public | 1.1 |
| Recruitment arrangements (for publication) | K2_Recruitment materials_FR_FR_Study leaflet_public | 1.1 |
| Recruitment arrangements (for publication) | K2_Recruitment materials_HU_HU_GP letter_public | 2 |
| Recruitment arrangements (for publication) | K2_Recruitment materials_HU_HU_Study drug instructions_public | 2 |
| Recruitment arrangements (for publication) | K2_Recruitment materials_NL_NL_ICF Table top_public | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment materials_NL_NL_Patient booklet_public | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment materials_NL_NL_Study Trifold Leaflet_public | 2 |
| Recruitment arrangements (for publication) | K2_Recruitment materials_PT_PT_Patient booklet_public | 1 |
| Recruitment arrangements (for publication) | K2_Recruitment materials_PT_Study Leaflet_public | 1 |
| Recruitment arrangements (for publication) | Recruitment and Retention 20604 CZ CZ Instruction of medication usage For publication | 1 |
| Recruitment arrangements (for publication) | Recruitment and Retention 20604 ICF Tabletop for publication | 1 |
| Recruitment arrangements (for publication) | Recruitment and Retention 20604 Patient booklet for publication | 1 |
| Recruitment arrangements (for publication) | Recruitment and Retention 20604 Study Leaflet for publication | 1 |
| Recruitment arrangements (for publication) | Recruitment and Retention CZ CZ 20604 ICF Tabletop For publication | 1 |
| Recruitment arrangements (for publication) | Recruitment and Retention CZ CZ 20604 Patient Booklet For publication | 1 |
| Recruitment arrangements (for publication) | Recruitment and Retention CZ CZ 20604 Study drug intake V4 V7 For publication | 1 |
| Recruitment arrangements (for publication) | Recruitment and Retention CZ CZ 20604 Study Leaflet For publication | 1 |
| Recruitment arrangements (for publication) | Recruitment and Retention DE 20604 Leaflet For publication | 1 |
| Recruitment arrangements (for publication) | Recruitment and Retention DE 20604 Tabletop For publication | 1 |
| Recruitment arrangements (for publication) | Recruitment and Retention DE AT 20604 ICF tabletop For publication | 1 |
| Recruitment arrangements (for publication) | Recruitment and Retention DE AT 20604 Patient booklet For publication | 1 |
| Recruitment arrangements (for publication) | Recruitment and Retention DE AT 20604 Study leaflet For publication | 1 |
| Recruitment arrangements (for publication) | Recruitment and Retention ES ES 20604 ICF Tabletop For Publication | 1 |
| Recruitment arrangements (for publication) | Recruitment and Retention ES ES 20604 Patient flyer For Publication | 1 |
| Recruitment arrangements (for publication) | Recruitment and Retention ES ES 20604 Study flyer For Publication | 1 |
| Recruitment arrangements (for publication) | Recruitment and Retention HU HU 20604 ICF tabletop For publication | 1 |
| Recruitment arrangements (for publication) | Recruitment and Retention HU HU 20604 Patient booklet For publication | 1 |
| Recruitment arrangements (for publication) | Recruitment and Retention HU HU 20604 Study drug intake For publication | 1 |
| Recruitment arrangements (for publication) | Recruitment and Retention HU HU 20604 Study leaflet For publication | 1 |
| Recruitment arrangements (for publication) | Recruitment and Retention IT 20604 ICF Tabletop For Publication | 1 |
| Recruitment arrangements (for publication) | Recruitment and Retention IT 20604 Patient Booklet For Publication | 1 |
| Recruitment arrangements (for publication) | Recruitment and Retention IT 20604 Study Leaflet For Publication | 1 |
| Recruitment arrangements (for publication) | Recruitment and Retention Patient booklet For publication | 1 |
| Subject information and informed consent form (for publication) | ICF Expecting parents - female NO 20604 for publication | 1 |
| Subject information and informed consent form (for publication) | ICF Other ES 20604 Data Protection Appendix For Publication | 1 |
| Subject information and informed consent form (for publication) | IL1_ICF_PT_PT_Other 3_public | 2 |
| Subject information and informed consent form (for publication) | L1_ICF_CZ_CZ_ICF - Core clean_public | 7 |
| Subject information and informed consent form (for publication) | L1_ICF_CZ_CZ_ICF - Core short version clean_public | 7 |
| Subject information and informed consent form (for publication) | L1_ICF_CZ_CZ_Other 1_public | 3 |
| Subject information and informed consent form (for publication) | L1_ICF_CZ_CZ_Other 3_public | 2 |
| Subject information and informed consent form (for publication) | L1_ICF_CZ_CZ_Other 4_public | 1 |
| Subject information and informed consent form (for publication) | L1_ICF_CZ_CZ_Other 5_public | 3 |
| Subject information and informed consent form (for publication) | L1_ICF_DE_AT_main_public | 5 |
| Subject information and informed consent form (for publication) | L1_ICF_DE_AT_Other1_public | 3 |
| Subject information and informed consent form (for publication) | L1_ICF_DE_AT_Other2_public | 1 |
| Subject information and informed consent form (for publication) | L1_ICF_DE_AT_Other3_public | 2 |
| Subject information and informed consent form (for publication) | L1_ICF_DE_AT_Other4_public | 1 |
| Subject information and informed consent form (for publication) | L1_ICF_DE_DE_Core Legal Representative_public | 3 |
| Subject information and informed consent form (for publication) | L1_ICF_DE_DE_Core_public | 4 |
| Subject information and informed consent form (for publication) | L1_ICF_DE_DE_Other 1_public | 2.1 |
| Subject information and informed consent form (for publication) | L1_ICF_DE_DE_Other 4_public | 1.1 |
| Subject information and informed consent form (for publication) | L1_ICF_DE_DE_Other 5_public | 1 |
| Subject information and informed consent form (for publication) | L1_ICF_DE_DE_Other 6_public | 1 |
| Subject information and informed consent form (for publication) | L1_ICF_EN_PT_Study Main English_public_obsolete | 3 |
| Subject information and informed consent form (for publication) | L1_ICF_ES_ES_Expecting Parents Female_public | 3 |
| Subject information and informed consent form (for publication) | L1_ICF_ES_ES_Main_public | 4 |
| Subject information and informed consent form (for publication) | L1_ICF_ES_ES_Other 1_public | 4 |
| Subject information and informed consent form (for publication) | L1_ICF_ES_ES_Other 2_public | 1 |
| Subject information and informed consent form (for publication) | L1_ICF_ES_ES_Other 3_public | 1 |
| Subject information and informed consent form (for publication) | L1_ICF_ES_ES_Study Update_public | 3.1 |
| Subject information and informed consent form (for publication) | L1_ICF_FR_FR_Main ICF Addendum_public | 1 |
| Subject information and informed consent form (for publication) | L1_ICF_FR_FR_Main ICF_public | 3 |
| Subject information and informed consent form (for publication) | L1_ICF_FR_FR_Other 1_public | 1.2 |
| Subject information and informed consent form (for publication) | L1_ICF_FR_FR_Other 3_public | 2.1 |
| Subject information and informed consent form (for publication) | L1_ICF_HU_HU_Core authorised person_public | 4 |
| Subject information and informed consent form (for publication) | L1_ICF_HU_HU_Core regain legal capacity_public | 4 |
| Subject information and informed consent form (for publication) | L1_ICF_HU_HU_Core_public | 4 |
| Subject information and informed consent form (for publication) | L1_ICF_HU_HU_Other 1 authorised person_public | 1 |
| Subject information and informed consent form (for publication) | L1_ICF_HU_HU_Other 1 regain legal capacity_public | 1 |
| Subject information and informed consent form (for publication) | L1_ICF_HU_HU_Other 1_public | 1 |
| Subject information and informed consent form (for publication) | L1_ICF_HU_HU_Other 2_public | 2 |
| Subject information and informed consent form (for publication) | L1_ICF_HU_HU_Other 3 authorised person_public | 3 |
| Subject information and informed consent form (for publication) | L1_ICF_HU_HU_Other 3 regain legal capacity_public | 3 |
| Subject information and informed consent form (for publication) | L1_ICF_HU_HU_Other 3_public | 3 |
| Subject information and informed consent form (for publication) | L1_ICF_HU_HU_Other 4 authorised person_public | 2 |
| Subject information and informed consent form (for publication) | L1_ICF_HU_HU_Other 4 regain legal capacity_public | 2 |
| Subject information and informed consent form (for publication) | L1_ICF_HU_HU_Other 4_public | 2 |
| Subject information and informed consent form (for publication) | L1_ICF_IT_IT_Core _public | 6 |
| Subject information and informed consent form (for publication) | L1_ICF_IT_IT_other 1 _public | 3 |
| Subject information and informed consent form (for publication) | L1_ICF_IT_IT_other 3 _public | 1 |
| Subject information and informed consent form (for publication) | L1_ICF_IT_IT_other 4 _public | 2 |
| Subject information and informed consent form (for publication) | L1_ICF_NL_NL_Other 1_public | 4 |
| Subject information and informed consent form (for publication) | L1_ICF_NL_NL_Other 2_public | 4 |
| Subject information and informed consent form (for publication) | L1_ICF_NL_NL_Other 3_public | 1 |
| Subject information and informed consent form (for publication) | L1_ICF_NL_NL_Other 4_public | 1 |
| Subject information and informed consent form (for publication) | L1_ICF_NL_NL_Other_public | 4 |
| Subject information and informed consent form (for publication) | L1_ICF_NO_NO_ICF core_public | 5 |
| Subject information and informed consent form (for publication) | L1_ICF_PT_PT Study Main_public | 5 |
| Subject information and informed consent form (for publication) | L1_ICF_PT_PT_Information Sheet and Consent Form for Expecting Parents:Female Study Participant_publ | 2 |
| Subject information and informed consent form (for publication) | L1_ICF_PT_PT_Study Update_public | 1 |
| Subject information and informed consent form (for publication) | L1_SIS and ICF_Public_Other 2_FR_FR | 2 |
| Subject information and informed consent form (for publication) | L2_Other subject info material_HU_HU_Emergency Contact Card_public | 2 |
| Subject information and informed consent form (for publication) | Subject Questionnaires and Scales CZ EQ-5D-5L For publication | 1 |
| Subject information and informed consent form (for publication) | Subject Questionnaires and Scales HU HU 20604 EQ-5D-5L For publication | 1.3 |
| Synopsis of the protocol (for publication) | D1_Synopsis of Protocol ES ES _2023-503793-20-00_public | 3 |
| Synopsis of the protocol (for publication) | D1_Synopsis of Protocol_BG_BG_2023-503793-20-00_public | 3 |
| Synopsis of the protocol (for publication) | D1_Synopsis of Protocol_CZ_CZ_2023-503793-20-00_public | 3 |
| Synopsis of the protocol (for publication) | D1_Synopsis of Protocol_DE_AT_2023-503793-20-00_public | 3 |
| Synopsis of the protocol (for publication) | D1_Synopsis of Protocol_EL_GR_2023-503793-20-00_public | 3 |
| Synopsis of the protocol (for publication) | D1_Synopsis of Protocol_EN_2023-503793-20-00_Public | 3 |
| Synopsis of the protocol (for publication) | D1_Synopsis of Protocol_FR_FR_2023-503793-20-00_public | 3 |
| Synopsis of the protocol (for publication) | D1_Synopsis of Protocol_HU_HU_2023-503793-20-00_public | 3 |
| Synopsis of the protocol (for publication) | D1_Synopsis of Protocol_IT_IT_2023-503793-20-00_Public | 3 |
| Synopsis of the protocol (for publication) | D1_Synopsis of Protocol_LT_LT_2023-503793-20-00_public | 3 |
| Synopsis of the protocol (for publication) | D1_Synopsis of Protocol_NL_NL_2023-503793-20-00_public | 3 |
| Synopsis of the protocol (for publication) | D1_Synopsis of Protocol_NO_NO_2023-503793-20-00_public | 3 |
| Synopsis of the protocol (for publication) | D1_Synopsis of Protocol_PL_PL_2023-503793-20-00_public | 3 |
| Synopsis of the protocol (for publication) | D1_Synopsis of Protocol_PT_PT_2023-503793-20-00_public | 1 |
| Synopsis of the protocol (for publication) | D1_Synopsis of Protocol_SK_SK_2023-503793-20-00_public | 3 |
| Synopsis of the protocol (for publication) | D1_Synopsis of Protocol_SV_SE_2023-503793-20-00_public | 3 |
Application history
21 submissions — initial application plus substantial / non-substantial modifications
| # | Type | Code | Submitted | Reference MS | Conclusion | Decision date |
|---|---|---|---|---|---|---|
| 1 | INITIAL | IN | 2023-08-14 | Sweden | Acceptable 2023-09-27
|
2023-09-27 |
| 2 | SUBSTANTIAL MODIFICATION | SM-1 | 2023-12-21 | Sweden | Acceptable 2024-03-04
|
2024-03-04 |
| 3 | NON SUBSTANTIAL MODIFICATION | NSM-1 | 2024-04-16 | Acceptable 2024-03-04
|
2024-04-16 | |
| 4 | SUBSTANTIAL MODIFICATION | SM-2 | 2024-05-31 | Sweden | Acceptable 2024-08-21
|
2024-08-21 |
| 5 | NON SUBSTANTIAL MODIFICATION | NSM-2 | 2024-09-10 | Sweden | Acceptable 2024-08-21
|
2024-09-10 |
| 6 | SUBSTANTIAL MODIFICATION | SM-3 | 2024-09-11 | Acceptable | 2024-09-18 | |
| 7 | SUBSTANTIAL MODIFICATION | SM-4 | 2024-09-12 | Acceptable | 2024-09-24 | |
| 8 | SUBSTANTIAL MODIFICATION | SM-5 | 2024-09-16 | Acceptable | 2024-11-14 | |
| 9 | SUBSTANTIAL MODIFICATION | SM-6 | 2024-11-11 | Acceptable | 2024-11-26 | |
| 10 | SUBSTANTIAL MODIFICATION | SM-7 | 2024-12-03 | Acceptable | 2024-12-18 | |
| 11 | SUBSTANTIAL MODIFICATION | SM-8 | 2024-12-19 | Sweden | Acceptable 2025-03-10
|
2025-03-10 |
| 12 | SUBSTANTIAL MODIFICATION | SM-9 | 2025-05-15 | Acceptable | 2025-07-28 | |
| 13 | SUBSTANTIAL MODIFICATION | SM-10 | 2025-05-19 | Acceptable | 2025-05-23 | |
| 14 | SUBSTANTIAL MODIFICATION | SM-11 | 2025-06-04 | Acceptable | 2025-09-01 | |
| 15 | SUBSTANTIAL MODIFICATION | SM-12 | 2025-06-04 | Acceptable | 2025-07-29 | |
| 16 | SUBSTANTIAL MODIFICATION | SM-13 | 2025-06-05 | Acceptable | 2025-07-07 | |
| 17 | SUBSTANTIAL MODIFICATION | SM-14 | 2025-07-30 | Acceptable | 2025-09-02 | |
| 18 | SUBSTANTIAL MODIFICATION | SM-15 | 2025-07-31 | Acceptable | 2025-08-12 | |
| 19 | NON SUBSTANTIAL MODIFICATION | NSM-3 | 2025-09-04 | Sweden | Acceptable | 2025-09-04 |
| 20 | NON SUBSTANTIAL MODIFICATION | NSM-4 | 2025-10-02 | Sweden | Acceptable | 2025-10-02 |
| 21 | SUBSTANTIAL MODIFICATION | SM-16 | 2025-10-02 | Acceptable | 2025-10-29 |